Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
May 07 2020 - 6:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
its participation at the BofA Securities Virtual Healthcare
Conference 2020. Troy Wilson, Ph.D., J.D., President and Chief
Executive Officer, is scheduled to present an overview of the
company on Tuesday, May 12, 2020 at 3:40 p.m. ET / 12:40 p.m. PT.
The virtual conference will be held from May 12-14, 2020.
A live audio webcast of the presentation will be
available in the Investors section of Kura’s website at
www.kuraoncology.com, with an archived replay available for 30 days
following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical
company committed to realizing the promise of precision medicines
for the treatment of cancer. The Company’s pipeline consists of two
wholly owned small molecule drug candidates that target cancer
signaling pathways where there is a strong scientific and clinical
rationale to improve outcomes by identifying those patients most
likely to benefit from treatment. Kura’s most advanced drug
candidate is tipifarnib, a potent, selective and orally
bioavailable farnesyl transferase inhibitor currently in a
registration-directed trial in patients with recurrent or
metastatic HRAS mutant head and neck squamous cell carcinoma. The
Company’s pipeline is also highlighted by KO-539, a potent and
selective inhibitor of the menin-KMT2A(MLL) protein-protein
interaction currently in a Phase 1/2A clinical trial in patients
with relapsed/refractory acute myeloid leukemia. For additional
information about Kura, please visit the Company’s website at
www.kuraoncology.com.
Forward-Looking Statements
This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause
actual results to be materially different from historical results
or from any future results expressed or implied by such
forward-looking statements. Such forward-looking statements include
statements regarding, among other things, the efficacy, safety and
therapeutic potential of Kura’s product candidate tipifarnib.
Factors that may cause actual results to differ materially include
the risk that compounds that appeared promising in early research
or clinical trials do not demonstrate safety and/or efficacy in
later preclinical studies or clinical trials, the risk that Kura
Oncology may not obtain approval to market its product candidates,
uncertainties associated with performing clinical trials,
regulatory filings and applications, risks associated with reliance
on third parties to successfully conduct clinical trials, the risks
associated with reliance on outside financing to meet capital
requirements, and other risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. You are urged to consider
statements that include the words “may,” “will,” “would,” “could,”
“should,” “believes,” “estimates,” “projects,” “promise,”
“potential,” “expects,” “plans,” “anticipated,” “intends,”
“continues,” “designed,” “goal,” or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
company faces, please refer to the company’s periodic and other
filings with the Securities and Exchange Commission, which are
available at www.sec.gov. Such forward-looking statements are
current only as of the date they are made, and Kura Oncology
assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contacts
Company:Pete De SpainVice President, Investor
Relations &Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke
ICR(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale
Communications(619) 849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024